Join our daily newsletter At The Bell to receive exclusive market insights
- Orthocell (OCC) appoints internationally-recognised nerve surgeons Professor Christopher Dy and Professor David Brogan to its medical scientific advisory board
- The company says the appointments will assist with clinical development and US market access for OCC’s nerve repair medical device
- OCC says both surgeons have extensive clinical and research expertise, with significant experience advancing pre-clinical and clinical research programs
- The company believes the appointments will foster further collaborations, assist in discussions with the US FDA and present data and product experiences in clinical and other settings within the US nerve repair market
- Shares in OCC are up 2.78 per cent and trading at 37 cents at 12:56 pm AEDT
Orthocell (OCC) has appointed US-based nerve surgeons Professor Christopher Dy and Professor David Brogan to its medical scientific advisory board.
The company said the professors, based at Washington University and Barnes-Jewish Orthopedic Center, specialise in nerve transfer and peripheral nerve repair.
Orthocell believes the appointments will assist with clinical development and US market access for the company’s nerve repair medical device.
OCC Managing Director Paul Anderson said the company was delighted by the new appointments.
“These appointments, along with the recent appointment of Dr Ravi Thadhani to the Orthocell board of directors, adds significant depth to our US team and ability to execute our commercialisation plans,” Mr Anderson said.
The company said both surgeons brought with them an abundance of clinical and research expertise, including significant experience advancing pre-clinical and clinical research programs.
Professor Dy specialises in treating brachial plexus and peripheral nerve injuries through the use of nerve transfers, nerve reconstructions, nerve decompressions and carpal and cubital tunnel release.
Professor David Brogan is a multi-credentialled surgeon who specialises in treating conditions of the hand and upper extremities. He treats nerve injuries, including peripheral nerve injuries, compression neuropathies, complex microsurgical reconstruction, and upper extremity trauma.
OCC said the additions would help foster further collaborations, assist discussions with the US FDA and present data and product experiences in clinical and other settings within the US nerve repair market.
Shares in OCC were up 2.78 per cent and trading at 37 cents at 12:56 pm AEDT.
